Upload
isabella-marcia-long
View
219
Download
1
Embed Size (px)
Citation preview
Lipid Disorders and Management Lipid Disorders and Management in Diabetesin Diabetes
Om P. Ganda MDJoslin Diabetes Center
Harvard Medical school
Boston, MA
Web-conference, April 8, 2010Web-conference, April 8, 2010
1420
29
46
62
8592
130
0
50
100
150
<180 200-220 240-260
Controls
Type 2 diabetes
Stamler et al. Diabetes Care. 1993;16:434-444.
Ag
e-A
dju
ste
d C
VD
de
ath
s p
er1
0,0
00
per
son
-yea
rs
Plasma cholesterol (mg/dL)280
MRFIT: Cholesterol and CVD Mortality MRFIT: Cholesterol and CVD Mortality in Men With Type 2 Diabetesin Men With Type 2 Diabetes
Pathophysiology of Pathophysiology of Dyslipidemia in Type 2 DiabetesDyslipidemia in Type 2 Diabetes
Krauss RM. Krauss RM. Diabetes CareDiabetes Care. 2004;27:1496-1504.. 2004;27:1496-1504.
TG pool
High
Low
Smaller VLDL
IDL
Larger VLDL
Large LDL
Small LDL
HDL Smaller HDL
Remnants Smaller
LDL
LPLLPL LPLLPL
LPLLPL LPL/HLLPL/HL
CETPCETPTGTG
HLHL
LDLRLDLR
Rate ratio & 95% CISTATIN better PLACEBO better
0.4 0.6 0.8 1.0 1.2 1.4
The Heart Protection Study Collaborative Group. Lancet. 2003;361:2005-2016.
HPS: Major Vascular Events by LDL-HPS: Major Vascular Events by LDL-C and Prior DiabetesC and Prior Diabetes
24% SE 3 reduction (2P<.00001)
LDL-C & DIABETES SIMVASTATIN(10,269)
PLACEBO(10,267)
< 116 mg/dL Diabetes 191 (15.7%) 252 (20.9%)
No diabetes 407 (18.8%) 504 (22.9%)
116 mg/dL Diabetes 410 (23.3%) 496 (27.9%)
No diabetes 1,025 (20.0%) 1,333 (26.2%)
ALL PATIENTS 2,033 (19.8%) 2,585 (25.2%)
Subgroup* Placebo** Atorva**Hazard Ratio Risk Reduction (CI)
LDL-C ≥3.06 (120) 66 (9.5) 44 (6.1) 38% (9-58)
LDL-C <3.06 (120) 61 (8.5) 39 (5.6) 37% (6-58)
p=0.96
HDL-C ≥1.35 (54) 62 (8.4) 36 (5.2) 41% (11-61)
HDL-C <1.35 (54) 65 (9.6) 47 (6.4) 35% (5-55)
P=.71
Trig. ≥1.7 (150) 67 (9.6) 40 (5.5) 44% (18-62)
Trig. <1.7 (150) 60 (8.4) 43 (6.1) 29% (-5-52)P=.40
* units in mmol/L (mg/dL) ** N (% of randomised)
.2 .4 .6 .8 1 1.2
Favors Atorvastatin Favors Placebo
CARDS: Treatment Effect CARDS: Treatment Effect ononthe Primary End Points by the Primary End Points by SubgroupSubgroup
Colhoun HM, et al. Lancet 2004;364:685-696
Major Vascular Events with or without Diabetes: Effect per 1mM/L reduction in LDL-cholesterol Major Vascular Events with or without Diabetes: Effect per 1mM/L reduction in LDL-cholesterol
14 RCTs18686 with DM71370 without DM
CTT Collaborators Lancet 2008, 371: 117-125
No differences by Presence or absence of vascular disease, Other risk-factors, or baseline lipid levels
Total mortality RR 0-88 (0.84-0.91)
Meta-analysis of Intensive Statin Trials:Coronary Death or Myocardial Infarction
Cannon,CP et al JACC 2006; 48: 438-445
DM : Similar outcome
ARR : 0.77 vs 1.36 %/yr
Statins and Primary End PointsStatins and Primary End Points
30 3724 24 31 27
15 9
36
70 6376 76 69 73
85 91
64
0
20
40
60
80
100
Risk reduction (%) Events not avoided (%)
Kastelein et al. Kastelein et al. Eur Heart JEur Heart J. 2005;7(suppl F):F27-F33.. 2005;7(suppl F):F27-F33.
Ris
k o
f P
rim
ary
Eve
nt
(%)
Ris
k o
f P
rim
ary
Eve
nt
(%)
TG <150 mg/dL Associated With Lower Risk of CHD Events Independent of LDL-C Level
PROVE IT-TIMI 22 Trial
Miller M, et al. J ACC. 2008;51:724-730.
CH
D E
vent
a R
ate
Afte
r 30
Day
sc , %
Death, MI, and recurrent ACS ACS patients on atorvastatin 80 mg or pravastatin 40 mgAdjusted for age, gender, low HDL-C, smoking, hypertension, obesity, diabetes, prior statin therapy, prior ACS, peripheral vascular disease, and treatment
N = 4162
TG <150 TG ≥150
LDL-C ≥70
LDL-C <70
HR: 0.72P=.017
HR: 0.85P=.180
HR: 0.84P=.192
Referent
TNT: major CVD Events in Patients with LDL < 70 TNT: major CVD Events in Patients with LDL < 70 mg/dlmg/dl
Barter,P et al NEJM 2007; 357: 1301-1310
Lifestyle changes and secondary causes
Pharmacologic therapy
• Fibrate
• Niacin
• Omega-3 Fatty acids
Combination therapy
Management of Dyslipidemia beyond LDL
The ACCORD Study Group. N Engl J Med 2010;10.1056/NEJMoa1001282
ACCORD- Lipid Results
The ACCORD Study Group. N Engl J Med 2010;10.1056/NEJMoa1001282
ACCORD Lipid: Primary Outcome in Prespecified Subgroups
ADA Lipid Goals and Recommendations 2009 Lifestyle modifications
Primary LDL –C goal < 100 mg/dl ; If CVD:LDL-C < 70 mg/dl is an option Statin therapy added to lifestyle changes, regardless of baseline LDL , if
• Overt CVD; • Without CVD but age > 40 yr + one or more other CVD risk factors
Without overt CVD and age < 40 yr-Consider statin if LDL-C > 100 mg/dl or multiple risk factors , despite lifestyle therapy.
In drug treated patients, a reduction in LDL-C of ~30-40% from baseline , if LDL targets not achieved with maximum tolerated statin therapy.
Triglycerides < 150 mg/dl; HDL-C > 40 mg/dl (men),> 50 mg/dl (women): Desirable • Combination therapy to achieve lipid goals may be needed but outcome
studies pending.
Diabetes Care 2009; 32(suppl1): S13-S61
ADA and ACC Consensus Statement on Lipoprotein Management
TREATMENT GOALSTREATMENT GOALS LDL-C LDL-C (mg/dL)(mg/dL)
Non–HDL-C Non–HDL-C (mg/dL)(mg/dL)
ApoB ApoB (mg/dL)(mg/dL)
Highest-risk patientsHighest-risk patients
Including those with Including those with 1) Known CVD or 1) Known CVD or 2) Diabetes plus one or more additional 2) Diabetes plus one or more additional CVD risk factor*CVD risk factor*
< 70 < 100 < 80
High-risk patientsHigh-risk patients
Including those with Including those with 1) No diabetes or known clinical CVD but 2 1) No diabetes or known clinical CVD but 2 or more additional major CVD risk factors or more additional major CVD risk factors or or 2) Diabetes but no other CVD risk factors2) Diabetes but no other CVD risk factors
< 100 < 130 < 90
Brunzell JD et al. Diabetes Care. 2008;31:811-822.
*Smoking, HBP, f/h premature CHD*Smoking, HBP, f/h premature CHD
Algorithm for Apo-B Testing in Patients with Dyslipidemia
Order Lipid profile
LDL-C > 100mg/dl TG >500 mg/dl
Lifestyle + Statin RxGoal: LDL-C < 100 mg/dl
Treat TG to < 500 mg/dlFibrates and/or Fish oil if > 1000 mg/dl
CVD-yes CVD-No
Intensify Statin Rx Statin Rx if LDL > 100
LDL< 70, TG > 200* LDL< 100, TG > 200*Measure Apo-B
Apo-B >80mg/dl ApoB< 90mg/dl
Intensify LDL Rx or add Fibrate/Niacin Continue current Rx; may need Fibrate/ Niacin
Ganda, OP Endocrine Practice 2009; 15: 370-376Ganda, OP Endocrine Practice 2009; 15: 370-376 * 150 if fasting* 150 if fasting